Partow Kebriaei

Nov 5, 2024 | nature.com | Niveditha Ravindra |Zoe Bayliss Wong |Zoë C Wong |Jeffery J. Auletta |Yi-Bin Chen |Steven M. Devine | +4 more

AbstractMeasurable residual disease (MRD) in adults with acute myeloid leukemia (AML) in complete remission is an important prognostic marker, but detection methodology requires optimization. Persistence of mutated NPM1 or FLT3-ITD in the blood of adult patients with AML in first complete remission (CR1) prior to allogeneic hematopoietic cell transplant (alloHCT) associates with increased relapse and death after transplant.

Nov 4, 2024 | targetedonc.com | Partow Kebriaei

Partow Kebriaei, MD, Department of Stem Cell Transplantation and Cellular Therapy, Division of Cancer Medicine, MD Anderson Cancer Center, discusses when the optimal time for transplant is in patients with acute lymphoblastic leukemia (ALL). In recent years, advances in treatment have transformed options for patients with ALL, leading to deeper remissions and raising new questions around the optimal timing for bone marrow and stem cell transplants.

Oct 24, 2024 | nature.com | Niveditha Ravindra |Zoe Bayliss Wong |Zoë C Wong |Jeffery J. Auletta |Yi-Bin Chen |Steven M. Devine | +4 more

AbstractRoutine genetic profiling of acute myeloid leukemia (AML) at initial diagnosis has allowed subgroup specific prognostication, drug development, and clinical management strategies. The optimal approach for treatment response assessment for AML subgroups has not yet however been determined.

Oct 17, 2024 | nature.com | Niveditha Ravindra |Zoë C Wong |Jeffery J. Auletta |Steven M. Devine |Mark Litzow |Partow Kebriaei | +2 more

To the Editor:High relapse rates for patients despite potentially curative allogeneic hematopoietic cell transplant (alloHCT) remain a critical issue in acute myeloid leukemia (AML). Next-generation sequencing (NGS) represents a promising modality for measurable residual disease (MRD) testing in patients with AML, but the appropriate targets for monitoring must be defined [1,2,3,4,5,6,7].

Sep 29, 2024 | targetedonc.com | Partow Kebriaei

Partow Kebriaei, MD, Department of Stem Cell Transplantation and Cellular Therapy, Division of Cancer Medicine, MD Anderson Cancer Center, discusses what factors may influence the decision for transplant in patients with acute lymphoblastic leukemia (ALL) and how experts determine who is best fit for transplant. Transcription:0:09 | I think with regards to transplant and from the transplant side, we have made great strides, especially in the area of graft-vs-host disease prophylaxis.